HR Execs on the Move

Mighty Oak Medical

www.mightyoakmedical.com

 
Navigate. Dont complicate.™ Personalized patient-specific spine care starts here. Navigate. Dont complicate.™ Personalized patient-specific spine care starts here. Mighty Oak Medical named Solution Provider
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cosmo Bio USA

Cosmo Bio USA is a company that provides quality life science products from leading Japanese manufacturers to laboratories, research institutes, life science education and testing organizations throughout North America.

Kiwa Bio-Tech Products Group Corporation

Kiwa Bio-Tech Products Group Corporation is a Claremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turing Pharmaceuticals

Turing Pharmaceuticals is a fully integrated biopharmaceutical company focusing on patients with unmet medical needs. We are dedicated to helping patients, who often have no effective treatment options, by developing and commercializing innovative treatments.

Rénibus Therapeutics

Rénibus Therapeutics® Inc. | A biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.